Integrated Training in Pharmacological Sciences

项目总结 这是西奈山伊坎医学院培训计划的续订申请，目前 在其第17个年头。在之前的项目期间，我们开发了一个创新的药理学项目 帮助将西奈山确立为新生系统领域的领导者之一的科学 药理学。我们是为所有博士引入量化和计算培训的早期倡导者 生物医学科学的候选人，这仍然是我们课程的基石原则。在课程作业中， 学生通过解决问题和主动学习练习应用定量/计算方法， 和作为药物发现和药物作用基础的基本生物学概念在 促进参与的疾病背景。除了严谨和创新的课程外，学员还在 我们的计划受益于增强研究体验的活动，包括期刊俱乐部、工作中的- 进步研讨会，专注于职业发展的年度静修，以及年度系统药理学 提供网络机会的研讨会。接下来的项目期将建立在这些成功的基础上 并推出包括翻转教室在内的新举措，以最大限度地提高学员的灵活性，这是一门将 由制药行业的科学家共同授课，并对所有项目导师进行正式培训。 对于论文研究，受训者可以由42名资金雄厚、具有以下专业知识的研究人员中的任何一位进行指导 不同药理学领域的方法，如基于结构的药物设计，数学模型 病理生理学和药物作用，以及生物工程。学生解决的前沿问题必须 解决癌症、心血管疾病等疾病领域安全有效的治疗方法， 神经系统疾病、糖尿病、肾脏和肝脏疾病。事实证明，这种结构在以下方面非常有效 培养出成功的年轻科学家。在过去10年内完成该计划的学员 平均在5.1年内完成博士学位，通常总共发表了近5篇论文 (平均4.88)和2多篇第一作者出版物(平均2.2篇)，这是他们在芒特接受培训的结果 西奈半岛。项目毕业生在成功的职业生涯中共同解决了许多方面的问题 药理科学，在学术界和制药行业都是如此。我们的目标是继续 创新和培养将成为明天药理学领袖和解决紧迫问题的实习生 在药物开发方面需要新的方法。

PROJECT SUMMARY This is a renewal application of a training program at Icahn School of Medicine at Mount Sinai that is currently in its 17th year. In previous project periods, we have developed an innovative program in pharmacological sciences that has helped to establish Mount Sinai as one of the leaders in the nascent field of systems pharmacology. We were early advocates of introducing quantitative and computational training for all PhD candidates in biomedical sciences, and this remains the cornerstone principle of our curriculum. In coursework, students apply quantitative/computational approaches through problem solving and active learning exercises, and fundamental biological concepts underlying drug discovery and drug action are communicated within a disease context that promotes engagement. In addition to the rigorous and innovative curriculum, trainees in our program benefit from activities that enhance the research experience, including journal clubs, Works-in- Progress seminars, an annual retreat focused on career development, and an annual systems pharmacology symposium that provides networking opportunities. The coming project period will build on these successes and introduce new initiatives including flipped classrooms to maximize trainee flexibility, a new course that will be co-taught by pharmaceutical industry scientists, and formal training for all program mentors. For dissertation research, trainees can be mentored by any of 42 well-funded investigators with expertise in approaches in varied areas of pharmacology such as structure-based drug design, mathematical modeling of pathophysiology and drug action, and bioengineering. Students address cutting edge issues that must be solved to develop safe and effective therapeutics in disease areas such as cancer, cardiovascular disease, neurological disorders, diabetes, and kidney and liver disease. This structure has proven highly effective at producing successful young scientists. Trainees who have completed the program during the past 10 years have finished their PhDs in an average of 5.1 years and have typically produced nearly 5 total publications (average 4.88) and over 2 first author publications (average 2.2) resulting from their time in training at Mount Sinai. Program alumni have gone on to successful careers that collectively address many aspects of pharmacological sciences, both in academia and in the pharmaceutical industry. We aim to continue to innovate and develop trainees who will become tomorrow’s leaders in pharmacology and address the urgent need for new approaches in drug development.